Since chemoresistance is a limiting factor in the efforts to provide successful treatment for prostate cancer, it is critical to understand how GTP differentially overcomes therapeutic resistance and induces apoptosis in prostate cancer cells with varying types of p53 abnormalities. This evidence concerns the gene TP53 and Familial prostate cancer.